Clinical Trial Search

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Response Rate — 15.3 percentage of participants

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Progression Free Survival at Week 12 — 0; 0; 0; 0 participants — p=0.653

Primary: Response (Complete Response [CR] and Partial Response [PR]) — 1; 0; 0; 0 participants

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…

Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants

Primary: Number of Participants With Engraftment — 23 Participants

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Late Radiation Toxicities at 2 Years From the Start of Radiation Treatment — 0 Participants

Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants

Primary: Progression-free Survival (PFS) — 7.0; 20.0 weeks — p=<0.001

Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs

Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants

Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)

Primary: Number of Patients With Abdominal Recurrence or Death — 72; 73; 61; 60 Participants — p=0.955

Primary: Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy. — 13 percentage of pt with a partial response

Primary: Tumor Best Response Rate — 0 Participants

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Phase I: Maximum Tolerated Dose (MTD) of Trabectedin When Administered in Association With CP. — 0.50 mg/m^2

Primary: Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas — 11.1 percentage of particpants

Primary: Clinical Benefit Rate — 22 Participants

Primary: Overall Objective Response — 1; 21; 26 participants

Primary: Cohorts 1, 3, 4, 5, 6 and 7: Objective Response Rate (ORR) — 9.4; 9.4; 0.0; 16.1 Percentage of participants